- Company
- Kim Sang-pyo, appointed as Moderna Korea's new GM
- by Eo, Yun-Ho Aug 1, 2024 05:47am
- Moderna Korea appointed Kim Sang-pyo, the former head of AstraZeneca Korea, as the new General Manager. Moderna announced the appointment of Kim Sang-pyo as the new General Manager, effective on August 1st. Kim will head Moderna's subsidiary in South Korea, succeeding Sohn Ji-young, who led the company's establishment in the Korean marke
- Company
- Combination cancer immunotherapies show high synergy
- by Son, Hyung-Min Aug 1, 2024 05:47am
- Data demonstrating the effectiveness of the combination of cancer immunotherapies are being disclosed. Recently, Opdivo+Yerboy therapy has been shown to improve the survival duration when used as a first-line treatment of hepatocellular carcinoma (HCC). GI Innovation confirmed partial response (PR) using cancer immunotherapies as combination the
- Company
- Commercialization of global RSV vaccines in progress in KOR
- by Son, Hyung-Min Jul 31, 2024 05:52am
- A global respiratory syncytial virus (RSV) vaccine has entered late-stage clinical trials for the first time in Korea, testing its potential for commercialization. Pfizer recently received approval to initiate a Phase III clinical trial in Korea to evaluate the immunogenicity of its RSV vaccine. Moderna is applying for Japanese approval of its R
- Company
- Competition rises in 1st-line urothelial cell carcinoma mkt
- by Eo, Yun-Ho Jul 31, 2024 05:51am
- The battle for the first-line treatment market for urothelial cell carcinoma (bladder cancer) is heating up amongst anticancer drugs. In addition to the PD-L1 immuno-oncology drug Bavencio (avelumab), which is already being reimbursed in Korea, the PD-1 immuno-oncology drug Opdivo (nivolumab) in combination with cisplatin and gemcitabine,
- Company
- Clinical trials for K-pharma's new lung fibrosis drugs
- by Son, Hyung-Min Jul 31, 2024 05:51am
- Pharmaceutical and biotech companies in South Korea are developing new drugs for Idiopathic pulmonary fibrosis (IPF). BridgeBio's Bersiporocin has progressed to Phase 2 trials, and the company has recently completed registering patients for Phase 2 trials. Nextgen Bioscience received Phase 1 investigational new drug (IND) approval from the Minis
- Company
- Samsung Bioepis launches Stelara biosimilar Pyzchiva in EU
- by Hwang, Byung-woo Jul 30, 2024 05:52am
- Samsung Bioepis has launched Pyzchiva, its biosimilar version of Stelara (ustekinumab), in the European market. Pyzchiva was approved in Europe and Korea in April and was launched into the Korean market as Epyztek. The drug was approved in the U.S. in June. The company’s marketing partner, Sandoz, will take charge of its sales in Europ
- Company
- First patient dosing with Pluvicto imminent in Korea
- by Moon, sunh-ho Jul 30, 2024 05:52am
- Novartis Korea's prostate cancer drug Pluvicto, which has been in the spotlight since its approval by the Ministry of Food and Drug Safety, is gaining further attention as the company prepares to administer the first dose to patients in Korea. Pluvicto is a blockbuster drug that generated more than KRW 1 trillion in global sales last year and
- Company
- Pfizer's MM drug Elerexfio seeks reimb in KOR
- by Eo, Yun-Ho Jul 29, 2024 05:48am
- Pfizer is attempting reimbursement listing of its new multiple myeloma drug ‘Elerexfio’ in Korea. According to industry sources, Pfizer Korea recently submitted a reimbursement application for its relapsed-refractory multiple myeloma (RRMM) treatment q (elranatamab). The company promptly started its listing process after receiving
- Company
- Eylea biosimilar 'Afilivu' will be prescribed
- by Eo, Yun-Ho Jul 29, 2024 05:48am
- Samsung Bioepis' Eylea biosimilar 'Afilivu' is becoming available for prescription at general hospitals. Industry sources said that Afilivu (aflibercept), a macular degeneration treatment, has passed the drug committees (DC) of medical centers, including Seoul National University Hospital and Seoul National University Bundang Hospital.
- Company
- GC accelerates global entry…targets China and Vietnam
- by Her, sung-kyu Jul 29, 2024 05:48am
- The GC group accelerating its global market entry after exporting Alyglo to the U.S., seeking to expand its business to China and Vietnam. In particular, it chose to cooperate with China's CR Pharmaceutical Group after selling its Chinese subsidiary, and the company is also seeking to enter Southeast Asia by collaborating with local companies
